Trial Profile
A Dose Finding Study of the Efficacy of LAIS Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis. A prospective, double-blind, placebo-controlled randomized multi-centre trial.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2015
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms SMART 2
- Sponsors Lofarma S.p.A
- 03 Sep 2013 New trial record